For example, the KRYSTAL-10 and LOXO 101 trials were both active in Ireland: KRYSTAL-10 recruited at several Irish hospitals and investigated the use of a novel KRAS-inhibiting drug, adagrasib, to treat colorectal cancer patients who have the KRAS-activating G12C mutation136, while LOXO 101 investigated the use of larotrectinib to treat any cancer harbouring anNTRK gene fusion that has been confirmed via molecular assay137. This evidence concerns the gene KRAS and colorectal cancer.